Research programme: radiopharmaceutical diagnostics and therapeutics - Fuzionaire Theranostics/McGill University/Montreal Neurological Institute-Hospital
Latest Information Update: 28 Feb 2024
Price :
$50 *
At a glance
- Originator Fuzionaire Diagnostics; McGill University; Montreal Neurological Institute and Hospital
- Developer Fuzionaire Theranostics; McGill University; Montreal Neurological Institute and Hospital
- Class Antidementias; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neurodegenerative disorders; Traumatic brain injuries
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for research development in Neurodegenerative-disorders in Canada (Parenteral)
- 28 Feb 2024 No recent reports of development identified for research development in Neurodegenerative-disorders in Japan (Parenteral)
- 28 Feb 2024 No recent reports of development identified for research development in Neurodegenerative-disorders(Diagnosis) in Canada (Parenteral)